Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis

Hanrong Li; Huiming Jiang; Zhicheng Huang; Zhilin Chen; Nanhui Chen

doi:doi:10.18632/aging.204972

← Back

Research Paper Volume 15, Issue 16 pp 8325—8344

Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis

Figure 11. Drug sensitivity analysis. (A) BC patients with a high-risk score had a higher IC₅₀ value of eight therapeutic drugs compared with patients with a low-risk score. (B) BC patients with a high-risk score had a lower IC₅₀ value of many therapeutic drugs compared with patients with a low-risk score.